Related references
Note: Only part of the references are listed.ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study
Abbas Dehghan et al.
LANCET (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans
J. H. Choi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers
I. Ieiri et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
Richard H. Ho et al.
PHARMACOGENETICS AND GENOMICS (2007)
Identification and functional assessment of BCRP polymorphisms in a Korean population
Sang Seop Lee et al.
DRUG METABOLISM AND DISPOSITION (2007)
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)
Jun-ren Zhu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Role of BCRP 421C>A polymorphism on rosuvastatin pharynacokinetics in healthy Chinese males
Wei Zhang et al.
CLINICA CHIMICA ACTA (2006)
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
Yoshihisa Shitara et al.
PHARMACOLOGY & THERAPEUTICS (2006)
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein
LY Huang et al.
DRUG METABOLISM AND DISPOSITION (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management
K Kajinami et al.
ATHEROSCLEROSIS (2004)
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
C Özvegy-Laczka et al.
MOLECULAR PHARMACOLOGY (2004)
Functional analysis of SNPs variants of BCRP/ABCG2
C Kondo et al.
PHARMACEUTICAL RESEARCH (2004)
Rosuvastatin - A highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: Review of clinical trial data at 10-40 mg doses in dyslipidemic patients
H Schuster
CARDIOLOGY (2003)
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine
CP Zamber et al.
PHARMACOGENETICS (2003)
Share Paper
